KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Debt Ratio: 2012-2025

Historic Debt Ratio for Halozyme Therapeutics (HALO) over the last 12 years, with Sep 2025 value amounting to 0.68.

  • Halozyme Therapeutics' Debt Ratio fell 4.23% to 0.68 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.68, marking a year-over-year decrease of 4.23%. This contributed to the annual value of 0.73 for FY2024, which is 15.64% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Debt Ratio stood at 0.68 for Q3 2025, which was down 7.43% from 0.73 recorded in Q2 2025.
  • Halozyme Therapeutics' Debt Ratio's 5-year high stood at 0.88 during Q1 2023, with a 5-year trough of 0.06 in Q2 2022.
  • For the 3-year period, Halozyme Therapeutics' Debt Ratio averaged around 0.77, with its median value being 0.76 (2024).
  • As far as peak fluctuations go, Halozyme Therapeutics' Debt Ratio soared by 1,486.42% in 2021, and later tumbled by 36.03% in 2022.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Debt Ratio stood at 0.79 in 2021, then increased by 3.03% to 0.82 in 2022, then climbed by 5.76% to 0.86 in 2023, then dropped by 15.64% to 0.73 in 2024, then fell by 4.23% to 0.68 in 2025.
  • Its Debt Ratio was 0.68 in Q3 2025, compared to 0.73 in Q2 2025 and 0.69 in Q1 2025.